GYNECOLOGIC ONCOLOGY GROUP

妇科肿瘤组

• 批准号: 6632957
• 负责人: Philip J. DiSaia
• 金额: $ 959.22万
• 依托单位: GYNECOLOGIC ONCOLOGY GROUP
• 依托单位国家: 美国
• 财政年份: 1980
• 资助国家: 美国
• 起止时间: 1980-05-01 至 2004-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6632957
• 关键词: antineoplastics; cancer prevention; cervix neoplasms; clinical research; clinical trial phase III; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; drug resistance; female; female reproductive system neoplasm; hormone therapy; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer education; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer radiation therapy; neoplasm /cancer relapse /recurrence; neoplasm /cancer surgery; neoplasm /cancer vaccine; ovary neoplasms; patient care management; prognosis; quality of life; tissue resource /registry; uterus neoplasms; vulva neoplasms

The Gynecologic Oncology Group (GOG) is the foremost multi-disciplinary cooperative clinical trial research group devoted to the study of gynecologic malignancies. Since its inception in 1970, the GOG has been a recognized leader in the development of new forms of treatment and has relied on the phase III trial as the design to identify new information. Supporting that major activity are the concerted efforts of modality committees providing recent approaches and procedures in each of the relevant diagnostic and therapeutic disciplines. The GOG has an active, effective program in the study of new chemotherapeutic agents in gynecologic cancers and this program has introduced important findings for study in the Phase III setting. In patients with advanced cervical, endometrial and ovarian cancers, the GOG has defined significant improvement associated with the use of cisplatin. The GOG has performed a series of trials to examine the role of paclitaxel either as a single agent or in combination with other agents. Isofamide was found to be one of the most active single agents in squamous carcinoma of the cervix. The results of Phase III studies by the GOG have provided a new standard of treatment in suboptimal ovarian cancer using platin and taxol. Two recently completed trials of post-operative patients with intermediate risk endometrial and cervical cancer showed a significant improvement with adjuvant radiotherapy. The benefit of post-operative adjuvant chemotherapy has been confirmed for patients with totally resected, early stage ovarian cancer. In addition, the GOG has been active in developing new mechanisms to enhance translational research, cancer prevention and control and medical informatics. The Group has collaborative actively with the NCI in evaluating new data management collection and reporting systems. After more than 25 years, the GOG continues to be foremost in developing new strategies in the management of these cancers.

妇科肿瘤学组（GOG）是致力于研究妇科恶性肿瘤研究的最重要的多学科合作临床试验研究小组。自1970年成立以来，GOG一直是开发新形式治疗的公认领导者，并依靠第三阶段试验作为确定新信息的设计。支持主要活动的是模式委员会的一致努力，该委员会在每个相关的诊断和治疗学科中提供了最新的方法和程序。 GOG在研究妇科癌症的新化学治疗剂方面具有积极的有效计划，该计划在III期设置中引入了重要的研究结果。在患有晚期宫颈，子宫内膜和卵巢癌的患者中，GOG定义了与顺铂有关的显着改善。 GOG已经进行了一系列试验，以检查紫杉醇作为单一药物或与其他药物结合的作用。发现异氧化胺是子宫颈鳞状癌中最活跃的单一药物之一。 GOG的III期研究结果使用Platin和紫杉醇提供了次优卵巢癌的新治疗标准。最近完成的两项术后术后患者的试验中间风险子宫内膜癌和宫颈癌的试验显示出辅助放射疗法的显着改善。对于完全切除的早期卵巢癌患者，已证实术后辅助化疗的好处。此外，GOG一直积极开发新机制，以增强转化研究，预防癌症和控制和医学信息学。该小组与NCI积极合作评估新的数据管理收集和报告系统。经过25年以上，GOG在制定这些癌症管理的新策略方面仍然是最重要的。